AOD9064 5mg
INTRODUCING
AOD9064
Frag 176-191, also known as AOD9604, is a synthetic peptide derived from a fragment of human growth hormone (hGH). It comprises amino acids 176-191 of the hGH sequence and has been shown to possess some of the fat-reducing properties of hGH without the adverse effects typically associated with full-length hGH administration. Frag 176-191 has attracted interest for its potential use in promoting fat loss and regulating energy metabolism.
Previous and ongoing research on Frag 176-191 has focused on several key areas:
1.Fat loss and metabolism: Frag 176-191 has been shown to stimulate lipolysis (breakdown of fat) and inhibit lipogenesis (formation of fatty acids) in animal models, suggesting potential benefits for weight loss and improved metabolic health.
2. Energy expenditure: Studies have suggested that Frag 176-191 may increase energy expenditure, which could help to promote weight loss and improve metabolic health.
3. Safety and efficacy: Frag 176-191 has been investigated for its safety and efficacy in comparison to full-length hGH, with studies suggesting that it may possess similar fat-reducing properties without some of the adverse effects associated with hGH administration.
Current research on Frag 176-191 is focused on further understanding its mechanisms of action, optimizing its therapeutic applications, and investigating its safety and efficacy in various populations and medical conditions. Some recent research papers related to Frag 176-191 include:
1.Heffernan, M., et al. (2016). “Effects of oral administration of AOD9604 and BRL37344 on tibial bone mechanical properties in growth hormone-deficient lit/lit mice.” Growth Hormone & IGF Research, 28, 29-33. [This study investigates the effects of Frag 176-191 and another compound on bone mechanical properties in growth hormone-deficient mice.]
2. Wu, Z., et al. (2014). “AOD9604, a peptide derived from human growth hormone, suppresses inflammation via regulation of JNK and NF-κB pathway.” European Journal of Pharmacology, 740, 60-65. [This study explores the anti-inflammatory effects of Frag 176-191 and its potential mechanisms of action.]
3. Stier, H., et al. (2013). “Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of AOD9604, an orally-active growth hormone analogue, in healthy volunteers.” British Journal of Clinical Pharmacology, 76(5), 663-672. [This study investigates the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of Frag 176-191 in healthy volunteers.]